• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • Important Items in China Pre-NDA Meetings for Innovative Drug Approvals

Important Items in China Pre-NDA Meetings for Innovative Drug Approvals

Monday, 20 December 2021 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

Important Items in China Pre-NDA Meetings for Innovative Drug Approvals

On November 26, 2021, the CDE (Center for Drug Evaluation) under the NMPA (National Medical Products Administration) published (No.48-2021) the technical requirements including common pharmacology issues for Pre-NDA meetings prior to innovative drugs going to market.

The Pre-NDA meeting is important to the approval of the NDA (New Drug Application) whilst focusing on key areas beneficial to the launch of new drug products, and providing applicants with ideas to improve the quality and efficiency of communication between applicants and the regulator.

The technical requirements addressed the following common issues:

  • API synthesis starting material selection
  • API pharmacological change research
  • API-related substances research and control
  • Research on mutagenic impurities
  • API quality control projects
  • Formulation change studies
  • Formulation degradation impurity research
  • Formulation quality control program and formulation dissolution
  • Release studies and other aspects of common pharmacy issues and general requirements

The technical requirement also stressed that major pharmacological changes should be completed as soon as possible before the start of clinical trials. If major pharmacological changes occur after the end of the clinical trial, the drug registration process may be affected.

In order to encourage the R&D and submission to accelerate the marketing process of innovative drugs, the NMPA supports applicants to resolve pharmacology-related issues during clinical trials through communication channels such as pre-application meeting for new drug clinical trials (Pre-IND meeting), end of phase II clinical trial for new drugs (EOP II)/pre-initiation meeting for phase III clinical trials (Pre-III meeting) at different research stages.

By Sun Jinlin and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: drugs, Innovative drugs, NDA, New Drug Applications, Pre-NDA

What you can read next

china cosmetics label requirements
China Cosmetics Label Requirements for Ingredients added to Cosmetic Raw Materials
china gmp for pharmaceutical packaging
China GMP for Pharmaceutical Packaging Materials (Draft for comments)
CCC Relevant Product Groups Updated

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • GB9706 standards for medical electrical equipment

    GB9706 standards for medical electrical equipment – implementation details clarified

    GB9706 standards are important reference guidel...
  • Microbial limits for non-sterile chemical drugs

    Microbial limits for non-sterile chemical drugs, API and excipients – new guidelines issued

    Microbial limits for non-sterile chemical drugs...
  • Medical Device Supplementary Notice Period

    China’s Medical Device Supplementary Notice Period reverts to a one-year period

    China’s Medical Device Supplementary Notice Per...
  • Dental adhesive products registration review guidelines

    Dental adhesive products registration review guidelines issued by the CMDE

    Dental adhesive products registration review gu...
  • China’s Toothpaste Supervision & Administration Regulation

    China’s New Toothpaste Supervision & Administration Regulation: A brief guide

    China’s Toothpaste Supervision & Administra...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP